Home › Free Stock Grades › SRPT
Sarepta Therapeutics, Inc. (SRPT) Stock Grade
SRPT · Healthcare
B
Market Cap
$2.3B
P/E Ratio
—
Revenue Growth (YoY)
+15.6%
Net Margin
-32.5%
Return on Equity
—
Dividend Yield
None
About Sarepta Therapeutics, Inc.'s fundamentals
Sarepta Therapeutics is a $2.3 billion biotechnology company currently unprofitable, with a net margin of -32.5% and a reported net loss in its latest annual statement. The company is growing revenue at a solid 15.6% year-over-year pace, indicating expanding commercial traction despite operating losses. With no dividend payment and negative profitability metrics, the company is reinvesting cash into development and commercialization of its product pipeline rather than returning capital to shareholders.